Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In-Home Versus In-Clinic Subcutaneous Nivolumab Administration
NCT06265285Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Apr 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in melanoma, urothelial carcinoma (UC), esophageal carcinoma, gastroesophageal junction carcinoma (GEJ), renal cell carcinoma (RCC), sponsored by Mayo Clinic. Started Apr 2024; status: recruiting.
02
Drugs
03
Conditions
melanomaurothelial carcinoma (UC)esophageal carcinomagastroesophageal junction carcinoma (GEJ)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06265285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06265285.